Technical analyst Anil Singhvi is bullish on Jubilant Life Sciences Ltd and has maintained 'buy' rating on the stock.

According to the analyst, the investors can buy the stock to achieve an intra-day target of Rs 172.

Mr. Singhvi said that the stock can be purchased with a stop loss of Rs 163.

The stock of the company, on March 08, closed at Rs 165.70 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 413.20 and a low of Rs 160 on BSE.

Current EPS & P/E ratio stood at 22.02 and 7.54 respectively.

Jubilant Life Sciences (JLS) declared that it is establishing a manufacturing facility to create Symtet, a key constituent for producing insecticide 'Chlorpyrifos', at Bharuch in the state of Gujarat, as part of its nearly Rs 350 crore capacity growth programs for the coming financial year.

The company said that it will establish a manufacturing facility in the SEZ, at Bharuch, for the chemical commercially named as Symtet/TCP, which will have an annual capacitance of 24,000 tonne.

The novel facility will also make chlorinated pyridine derivatives with a yearly fabrication of 5,000 tonne.

JLS Executive Director Finance R Sankaraiah stated, "The company has earmarked Rs 350 crore for capacity expansion in 2011-12. The new project in Gujarat would be a part of this capacity expansion."

But, JLS has not revealed the investment details of the project.